- Home
- / ALX Oncology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ALX Oncology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.4
2024-10-29
Market Capitalization
$77.5 M
2024-10-29
Revenue
$1.2 M
FY, 2020
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.2M | |||||
| General and administrative expense | 14.8M | 23.4M | 29.0M | 28.5M | 26.1M | 23.9M |
| Operating expense total | 43.8M | 83.6M | 127.4M | 142.5M | 100.8M | |
| EBIT | (43.7M) | (83.6M) | (127.4M) | (170.3M) | (142.5M) | (104.0M) |
| EBIT margin, % | -3694.0% | |||||
| Interest income | 10.6M | 9.4M | 4.0M | |||
| Interest expense | 811.0K | 13.0K | 4.3M | 1.6M | 1.7M | |
| Pre tax profit | (45.5M) | (83.5M) | (123.4M) | (160.8M) | (134.8M) | (101.7M) |
| Income tax expense | 241.0K | (21.0K) | 64.0K | |||
| Net Income | (45.7M) | (83.5M) | (123.5M) | (160.8M) | (134.8M) | (101.7M) |
| EPS | (3.0) | (3.0) | (2.6) | (1.9) |